Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer.

Bernardo Leon Rapoport Annette J Theron Daniel A Vorobiof Lizanne Langenhoven Jacqueline M Hall Ronwyn I Van Eeden Teresa Smit Sze-Wai Chan Michael C Botha Johann I Raats Margriet De Necker Ronald Anderson

Published in: Lung cancer management (2020)

Pretreatment elevated NLR values are associated with poor outcomes in patients with recurrent metastatic non-small-cell lung cancer treated with nivolumab.

Keyphrases

patients undergoing
squamous cell carcinoma
small cell lung cancer
type diabetes
adipose tissue
metabolic syndrome
replacement therapy